Virtus InfraCap U.S. Preferred Stock ETF (ARCA: PFFA)

Dernières nouvelles pour Virtus InfraCap U.S. Preferred Stock ETF (ARCA:PFFA)

Virtus InfraCap U.S. Preferred Stock ETF

Real Estate

Financial Services

Industrials

Energy

Other

Utilities

Communication Services

Consumer Cyclical

Healthcare

Technology

Consumer Defensive

Basic Materials

<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"><div class="wp-block-embed__wrapper">
https://www.youtube.com/watch?v=AXSt2PzWYbY
</div></figure>

Infrastructure Capital Advisors

Under normal market conditions, the fund will invest not less than 80% of its net assets (plus the amount of any borrowings for investment purposes) in U.S. preferred stock, and in derivatives and other instruments that have economic characteristics similar to such investments. The Sub-Adviser actively manages the fund's assets pursuant to a variety of quantitative, qualitative and relative valuation factors. The fund is non-diversified.

Sce Trust Iii

SLM Corp Pb Pref

Nextera Energy Inc

Global Net Lease Inc

Energy Transfer Lp

Ftai Aviation Ltd

Rlj Lodging Trust

Nustar Energy Lp

New York Mortgage Trust IncPref

The iShares Semiconductor ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOXX#NASDAQ">SOXX</a>) finds itself at a crossroads. JPMorgan&#8217;s latest technical update reveals that the Philadelphia Semiconductor Index, a benchmark for the iShares Semiconductor ETF, has largely&nbsp;been propelled&nbsp;to&nbsp;the upper limit of&nbsp;a multimonth trading range by a rally in AI-related stocks. 
Yet the index now faces stiff resistance near 5,400, raising questions about its ability to sustain a long-term rally without support from the more cyclical analog <a href="https://www.benzinga.com/topic/semiconductors">semiconductor </a>group.
AI has been transforming industries and <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/01/42921523/nvidias-lead-expands-analyst-says-ai-demand-remains-very-strong">driving demand</a> for semiconductors. Leading chipmakers like Nvidia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) and Broadcom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) have led the rally, riding the AI wave. Nvidia&#8217;s advanced Blackwell GPUs and Broadcom's custom AI accelerators enjoy solid market interest. JPMorgan warns the heavy reliance on AI names could be risky, as the analog semiconductor group, closely linked with global manufacturing cycles, dawdles.
JPMorgan said the analog segment is not performing up to par and this is consistent with with the PMI level globally being around 50, indicating a certain level of pessimism. SOXX would need participation from this segment to break out of its trading range and sustain a broader rally.
&#8220;We also highlight just how correlated the analog group is to the global manufacturing cycle, with the current pricing roughly in line with a 50 global manufacturing PMI reading. That coincides with the US exceptionalism theme that seems priced across markets in other asset classes,&#8221; JPMorgan analysts said in a note. 
<h3 class="wp-block-heading">Why SOXX Still Holds Promise</h3>
Despite these concerns, SOXX offers a strong value proposition for investors looking for exposure to the semiconductor industry&#8217;s growth. The ETF, which focuses solely on chip companies, is expected to capitalize on the AI spending boom. With Nvidia, Broadcom and Advanced Micro Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) accounting for significant portions of its portfolio, SOXX bets heavily on the sector's leaders.
Microsoft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), Amazon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), Alphabet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) and Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) alone are projected to spend $300 billion on AI infrastructure by 2025, according to a November report by Business Insider citing Morgan Stanley. This influx of investment bodes well for the ETF, which has holdings in nearly every key hardware stock involved in the AI revolution. With a 7.84% weighting in the ETF, Nvidia will expose investors to its industry leading advancements, whereas diversification within the AI hardware universe will come from Broadcom (with 10.94% weightage) and AMD (6.87%).
<h3 class="wp-block-heading">Watchful Optimism</h3>
JPMorgan's analysis brings both opportunities and risks for iShares Semiconductor ETF to the spotlight. For instance, a 2-point improvement in global manufacturing PMI could open up a 20% upside for the analog semiconductor group, as analyzed by JP Morgan. This can potentially improve the overall performance of iShares Semiconductor ETF. Conversely, the dependence of the ETF on AI-driven growth makes it sensitive to setbacks of the highly fragmented broader semiconductor market.
See Next: 
<ul>
<li><a href="https://www.benzinga.com/25/01/42922934/oil-stocks-rally-on-anticipation-of-stricter-russian-sanctions-heres-how-etfs-are-reacting">Oil Stocks Rally On Anticipation Of Stricter Russian Sanctions: Here&#8217;s How ETFs Are Reacting</a></li>
</ul>
Photo: Shutterstock.

Analyst Color

Equities

News

Sector ETFs

Markets

Analyst Ratings

Tech

ETFs

AMZN

AVGO

GOOGL

MSFT

NVDA

iShares PHLX SOX Semiconductor Sector Index Fund

SOXX

Semiconductor ETF Faces Key Resistance In AI-Driven Surge: Analyst

Palantir Technologies Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>) joined the prestigious <a href="https://www.benzinga.com/topic/nasdaq-100">Nasdaq-100 index</a> on Dec. 23, a milestone often seen as a vote of confidence for companies with promising growth trajectories.
Yet, rather than boosting investor sentiment, the stock has since tumbled over 15%, vastly underperforming broader market benchmarks. 
For comparison, the SPDR S&amp;P 500 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) slipped just 0.87%, while the tech-heavy Invesco QQQ Trust, Series 1 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) fell a modest 1.45% during the same period.
<h1 class="wp-block-heading">High Expectations, Harsh Reality</h1>
Inclusion in the Nasdaq-100 is usually accompanied by a wave of enthusiasm. However, Palantir&#8217;s slide underscores mounting challenges facing high-growth tech firms. 
Market sentiment has turned cautious as investors question the sustainability of lofty valuations amid economic uncertainty and rising interest rates. Despite expanding its footprint in commercial sectors and securing high-profile contracts, Palantir faces skepticism over its cost structure and pathway to profitability. 
Palantir's heavy focus on government contracts and its complex business model have become key points of scrutiny. 
Read Also: <a href="https://www.benzinga.com/markets/equities/25/01/42891906/palantir-cto-shyam-sankar-challenges-automations-potential-as-selling-pressure-mounts-what-have-we-been-doing-for-20-years">Palantir CTO Shyam Sankar Challenges Automation&#8217;s Potential As Selling Pressure Mounts: &#8216;What Have We Been Doing For 20 Years?&#8217;</a>
<h1 class="wp-block-heading">Palantir Stock: Mixed Signals From Moving Averages</h1>
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent011025&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="630" height="494" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/10134353/Screenshot-2025-01-11-at-12.13.39-AM.png" alt="" class="wp-image-728797" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/10134353/Screenshot-2025-01-11-at-12.13.39-AM.png 630w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/10134353/Screenshot-2025-01-11-at-12.13.39-AM-300x235.png 300w" sizes="(max-width: 630px) 100vw, 630px" /></a></figure>
<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent011025&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">Chart created using Benzinga Pro</a>
At $67.40, PLTR stock shows divergence across key moving averages:
<ul>
<li>The eight-day SMA (simple moving average) at $73.68 and 20-day SMA at $75.60 both indicate a bearish outlook, reflecting downward short-term momentum.</li>
<li>Meanwhile, the 50-day SMA at $66.53 suggests a bullish signal, highlighting possible mid-term recovery potential.</li>
<li>The 200-day SMA at $38.10 reinforces a bullish stance, underscoring investor optimism over the long term.</li>
</ul>
<h1 class="wp-block-heading">MACD, RSI Indicators Suggest Tentative Strength</h1>
The MACD (moving average convergence/divergence) indicator reads 1.16, signaling bullish momentum as upward pressure builds. 
The Relative Strength Index (RSI) at 41.97 remains in the neutral territory, implying PLTR stock is neither overbought nor oversold, indicating a balanced market sentiment.
<h1 class="wp-block-heading">Balancing Bearish Signals With Recovery Potential</h1>
Despite short-term bearish indicators, Palantir&#8217;s ability to maintain key support levels signals potential for recovery. The contrast between short-term pressure and long-term bullish trends highlights the importance of closely monitoring price movements.
With market dynamics shifting, investors should brace for continued volatility, keeping a watchful eye on technical developments and broader economic conditions.
As tech stocks face heightened scrutiny, Palantir's journey on the Nasdaq-100 will be a crucial gauge of whether the company can realign investor sentiment and stabilize its market trajectory.
Read Also: 
<ul>
<li><a href="https://www.benzinga.com/news/global/25/01/42910173/palantir-co-founder-joe-lonsdale-sets-realistic-expectations-for-elon-musks-doge-initiative-next-trillion-will-be-a-lot-harder">Palantir Co-Founder Joe Lonsdale Sets Realistic Expectations For Elon Musk&#8217;s DOGE Initiative: &#8216;Next Trillion Will Be A Lot Harder&#8217;</a></li>
</ul>
Photo: Shutterstock

Long Ideas

Technicals

Trading Ideas

PLTR

Palantir's Nasdaq-100 Hype Fades As Stock Sinks 15% Post-Inclusion

UBS analyst Joshua Spector upgrades Westlake (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WLK#NYSE">WLK</a>) from Neutral to Buy and maintains the price target from $144 to $144.

Upgrades

Price Target

UBS Upgrades Westlake to Buy, Maintains Price Target to $144

UBS analyst Joshua Spector maintains Corteva (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTVA#NYSE">CTVA</a>) with a Buy and lowers the price target from $74 to $73.

CTVA

UBS Maintains Buy on Corteva, Lowers Price Target to $73

On Thursday, Truist initiated coverage on BioNTech SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>), a famed COVID-19 vaccine maker, in collaboration with Pfizer Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>).
BioNTech is transitioning from a COVID-focused narrative to a story centered on oncology drug development <a target="_blank" href="https://www.benzinga.com/24/12/42370209/why-is-biontech-stock-trading-higher-on-friday" rel="noreferrer noopener">and upcoming catalysts.</a>
The analyst, Asthika Goonewardene, writes that BNT327 is at the forefront, a promising drug in an innovative class that could challenge and potentially surpass the PD-1 category, which generated over $42 billion in 2023.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41866389/biontech-earns-upgrade-from-goldman-sachs-as-investment-thesis-shifts-toward-cancer-potential" rel="noreferrer noopener">BioNTech Earns Upgrade From Goldman Sachs As Investment Thesis Shifts Toward Cancer Potential</a>
While Summit Therapeutics Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>) ivonescimab may have a head start in certain areas, BioNTech&#8217;s stronger financial position and pipeline of complementary products give it a strategic edge. With several key data updates expected in 2025, the stock appears well-positioned for long-term growth, the analyst adds.
In November, BioNTech agreed to acquire&nbsp;Biotheus, a clinical-stage biotechnology company focused on discovering and developing antibodies for&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41949384/biontech-boosts-oncology-strategy-with-800-million-china-based-biotheus-acquisition" rel="noreferrer noopener">oncological or inflammatory diseases</a>.
With the acquisition, BioNTech will obtain full global rights to the late-stage clinical asset BNT327/PM8002, an investigational bispecific antibody targeting PD-L1 and VEGF-A.
Truist initiated with a Buy rating and a <a target="_blank" href="https://www.benzinga.com/quote/BNTX/analyst-ratings" rel="noreferrer noopener">price target of $172</a>.
BioNTech&#8217;s oncology pipeline was previously seen as limited in value outside BNT316. However, with BNT327 gaining traction and new data expected in 2025 to clarify the potential of other pipeline assets, there is room for greater investor appreciation of the company&#8217;s oncology portfolio, Truist analyst adds.
Goonewardene also writes that <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41715307/biontech-variant-adapted-covid-19-vaccines-do-well-in-q3" rel="noreferrer noopener">COVID-19 remains a significant factor</a> in BioNTech&#8217;s stock performance and that COVID-related developments will continue to influence BioNTech&#8217;s stock.
The analyst highlights that BNT327 could be the first drug approved in the U.S. and Europe for key conditions like triple-negative breast cancer and small cell lung cancer, potentially generating around $2 billion at peak sales.
For non-small cell lung cancer, Truist expects BNT327 to follow shortly, contributing over $4 billion in revenue.
Price Action: BNTX stock is up 0.55% at $122.82 at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/01/42918973/wayfair-waves-goodbye-to-germany-heres-why" target="_blank" rel="noreferrer noopener">Wayfair Waves Goodbye To Germany &#8211; Here&#8217;s Why</a></li>
</ul>
Image via Shutterstock.

Biotech

Large Cap

Initiation

General

BNTX

SMMT

BioNTech Positioned For Solid Growth Amid Oncology Transition: Analyst

WIIM

SPGI

S&P Global shares are trading lower after Wells Fargo cut its price target on the stock from $620 to $617.

UBS analyst Joshua Spector maintains Avery Dennison (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVY#NYSE">AVY</a>) with a Neutral and lowers the price target from $235 to $207.

UBS Maintains Neutral on Avery Dennison, Lowers Price Target to $207

UBS analyst Curt Woodworth maintains Ardagh Metal Packaging (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMBP#NYSE">AMBP</a>) with a Neutral and lowers the price target from $4.25 to $2.75.

AMBP

UBS Maintains Neutral on Ardagh Metal Packaging, Lowers Price Target to $2.75

STNG

TALO

TRGP

VTLE

Shares of oil, gas and tanker companies are trading higher following reports suggesting the US is preparing sanctions against Russian oil and gas.

UBS analyst Joshua Spector maintains Berry Global Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BERY#NYSE">BERY</a>) with a Neutral and lowers the price target from $75 to $72.

BERY

UBS Maintains Neutral on Berry Global Gr, Lowers Price Target to $72

Macro Economic Events

Economics

Oil is trading higher following reports suggesting the US is preparing sanctions against Russian oil and gas.

UBS analyst Curt Woodworth maintains Crown Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCK#NYSE">CCK</a>) with a Buy and lowers the price target from $113 to $108.

UBS Maintains Buy on Crown Holdings, Lowers Price Target to $108

UBS analyst Joshua Spector maintains Sealed Air (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SEE#NYSE">SEE</a>) with a Neutral and lowers the price target from $39 to $37.

UBS Maintains Neutral on Sealed Air, Lowers Price Target to $37

Affirm Holdings's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AFRM#NYSE">AFRM</a>) short percent of float has fallen 8.86% since its last report. The company recently reported that it has 15.02 million shares sold short, which is 5.66% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.11 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Affirm Holdings Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736538321_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Affirm Holdings has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Affirm Holdings's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Affirm Holdings's peer group average for short interest as a percentage of float is 5.01%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

AFRM

Peering Into Affirm Holdings's Recent Short Interest

Philip Morris Intl's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PM#NYSE">PM</a>) short percent of float has risen 23.73% since its last report. The company recently reported that it has 11.39 million shares sold short, which is 0.73% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.32 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Philip Morris Intl Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736538315_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Philip Morris Intl has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Philip Morris Intl's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Philip Morris Intl's peer group average for short interest as a percentage of float is 1.81%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

(PM) - Analyzing Philip Morris Intl's Short Interest

Colgate-Palmolive's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CL#NYSE">CL</a>) short percent of float has risen 4.59% since its last report. The company recently reported that it has 9.29 million shares sold short, which is 1.14% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.19 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Colgate-Palmolive Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736538310_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Colgate-Palmolive has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Colgate-Palmolive's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Colgate-Palmolive's peer group average for short interest as a percentage of float is 6.28%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Looking Into Colgate-Palmolive's Recent Short Interest

Susquehanna analyst Biju Perincheril downgrades Array Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARRY#NASDAQ">ARRY</a>) from Positive to Neutral and lowers the price target from $9 to $7.

Downgrades

ARRY

Susquehanna Downgrades Array Technologies to Neutral, Lowers Price Target to $7

AENT

ALUR

BKNG

CVNA

New Oriental Education & Technology Group

GROV

MBLY

MMYT

RIME

SPGC

WRBY

YUMC

ZSPC

Shares of companies within the broader consumer discretionary sector are trading lower amid overall market weakness due to a rise in yields.

FFIE

LVWR

MULN

Shares of auto companies are trading lower amid overall market weakness due to a rise in yields.

Susquehanna analyst Biju Perincheril downgrades Sunnova Energy Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOVA#NYSE">NOVA</a>) from Positive to Neutral and lowers the price target from $14 to $4.5.

NOVA

Susquehanna Downgrades Sunnova Energy Intl to Neutral, Lowers Price Target to $4.5

2 Solid Yields From Preferred Stocks For Uncertain Times

It Is The Right Time To Be A Retirement Income Investor

$75,000 Is All You Need To Be Happy

Virtus InfraCap U.S. Preferred Stock ETF declares monthly distribution of $0.1675

Year Of The Dragon: Comprehensive Review Of My 2024 Stock Picks, And Current Ratings

Why 9.2%-Yielding PFFA Beats The Competition

6%-Yielding PFF Is On Sale, But I Am Not Buying

Invest In $100,000 Financial Freedom Portfolio For Accelerated Passive Income

PFFA: The Right Moment To Lock In This 9% Monthly Dividend

How I Plan To Invest $700,000 To Pay Bills With Dividends Forever

AAPL

AMLP

ARCC

BIZD

BLDP

BXSL

COLD

CPRI

CTAS

DLMAF

FDUS

FEPI

FVRR

GOLD

INTC

JEPI

JEPQ

KBDC

MAIN

MATW

MKTX

NVDY

PALL

PAXS

PFFA

PFFR

PLCE

PLTM

PPLT

QDTE

QYLD

SCHD

SOXL

SPYI

SRRTF

STAG

SVOL

THRM

TIXT

TQQQ

TRIP

UPWK

Press Releases

Virtus InfraCap ETFs (AMZA/PFFA/PFFR) Declare Monthly Distributions

Infrastructure Capital Advisors Declares Its Monthly Dividends: The InfraCap Small Cap Income ETF (SCAP) and InfraCap Equity Income Fund ETF (ICAP)

Infrastructure Capital Advisors Announces a Quarterly Dividend Increase: the Infracap Small Cap Income ETF (SCAP)

Infrastructure Capital Advisors Announces a Quarterly Dividend Increase for the Infracap Small Cap Income ETF (SCAP) and the Infracap Equity Income Fund ETF (ICAP)

Infrastructure Capital Announces a Quarterly Dividend Increase

AMZA

ICAP

SCAP

Comments

Virtus InfraCap U.S. Preferred Stock ETF

Actualités

Dernières nouvelles pour Virtus InfraCap U.S. Preferred Stock ETF (ARCA:PFFA)

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL